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Abstract
Staphylococcus aureus bacteraemia (SAB) is a leading cause of mortality and morbidity in both nosocomial and community settings. The
objective of the study is to explore epidemiological characteristics and predisposing risk factors associated with healthcare-associated
(HCA) and community-acquired (CA) SAB, and to evaluate any differences in mortality and efﬁcacy of initial antimicrobial therapy on
treatment outcome. We conducted a two-part analysis. First, a triple case–control study in which groups of HCA SAB with onset
‡48 h after hospital admission (HCA ‡48 h), HCA SAB with onset <48 h of hospital admission (HCA <48 h), and CA SAB were com-
pared with controls. Second, a cohort study including all patients with SAB was performed to identify factors associated with in-hospital
mortality. SAB was diagnosed in 165 patients over the study period (January 2007 to December 2007). Five variables were indepen-
dently associated with HCA ‡48 h SAB: presence of central venous catheter, solid tumour, chronic renal failure, previous hospitalization
and previous antibiotic therapy. Signiﬁcant risk factors for HCA <48 h SAB were: Charlson Comorbidity Index ‡3, previous hospitaliza-
tion, living in long-term care facilities and corticosteroid therapy. Factors independently associated with CA SAB were: diabetes mellitus,
HIV infection and chronic live disease. Patients with HCA <48 h SAB were signiﬁcantly more likely to receive initial inadequate anti-
microbial treatment than patients with CA or HCA ‡48 h SAB (44.8% versus 33.3% and 31.5%, respectively). Logistic-regression analysis
identiﬁed three variables as independent predictors of mortality: presentation with septic shock, infection with methicillin-resistant
S. aureus, and initial inadequate antimicrobial treatment. More than half of patients with SAB have MRSA strains and presentation with
septic shock, and inappropriate empirical therapy was associated with increased mortality.
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Introduction
Staphylococcus aureus bacteraemia (SAB) is a leading cause of
mortality and morbidity in both nosocomial and community
settings. Although the mortality rate has declined in some
countries as a result of improved quality of care [1], the
overall prevalence has increased in line with increasing use of
intravascular devices and an expanding ‘at-risk’ population
[1,2].
SAB has been studied in various patient populations meet-
ing selective criteria [3,4]. Notably, the investigation of bac-
teraemias caused by methicillin-resistant S. aureus (MRSA)
has become a major focus of interest over the past few
years. A number of studies have shown that the characteris-
tics of patients infected with MRSA differ from those of
patients with methicillin-susceptible S. aureus (MSSA) bactera-
emia [5]. Several studies, including one meta-analysis, have
suggested that MRSA bacteraemia is associated with a
signiﬁcantly higher mortality rate [5–9]. The proportion of
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nosocomial infections caused by MRSA continues to increase
in most countries, although with substantial geographical
variations [10]. Growing resistance to antibiotics may lead to
an increase in inadequate initial antimicrobial treatment
(IIAT) of infections.
We performed a prospective study in two Italian hospitals
to better understand the epidemiology of SAB. The objec-
tives of the study were to provide a view of epidemiological
characteristics and predisposing risk factors associated with
healthcare-associated (HCA) SAB in patients hospitalized for
48 h or more (HCA ‡48 h), HCA SAB with onset within
48 h of hospitalization (HCA <48 h), and community-
acquired (CA) SAB, and to evaluate differences in mortality
and efﬁcacy of initial antimicrobial therapy on treatment out-
come.
Materials and Methods
Setting and study design
This study was conducted in two Italian university hospi-
tals that admit c. 50 000 patients per year. The microbiol-
ogy laboratory database was used to identify prospectively
patients with SAB who were hospitalized between 1 Janu-
ary 2007 and 31 December 2007; such patients were
deﬁned by the presence of at least one positive blood cul-
ture and clinical features compatible with systemic inﬂam-
matory response syndrome. Each patient was included in
the study only once, at the time of the ﬁrst positive blood
culture. Patients were included only if a complete data
series could be obtained from their medical records.
Cases of polymicrobial bacteraemia were excluded. The
distributions of the case and control admissions through-
out the study period were similar.
Three case groups were deﬁned: group 1 consisted of
patients with HCA ‡48 h SAB, group 2 comprised patients
with HCA <48 h SAB, group 3 comprised those with CA
SAB. The control group consisted of patients with no posi-
tive clinical cultures from any site for S. aureus during their
hospitalization, and were matched 2 : 1 with the cases
according to the following criteria: hospital location (ward),
month of admission, and length of hospital stay at the time
of matching.
We conducted a two-part analysis. First, a triple case–
control study in which 112 patients in group 1, 29 patients
in group 2, and 24 patients in group 3 were compared with
224 (group 4), 58 (group 5), and 48 (group 6) control
patients, respectively, to determine factors associated with
the isolation of HCA ‡48 h, HCA <48 h or CA SAB.
The second part of the analysis was a cohort study includ-
ing all patients with SAB (group 1 plus group 2 plus group
3), to identify factors associated with in-hospital mortality
associated with SAB by using death within 30 days of the
ﬁrst positive blood culture as the outcome and comparing
survivors and non-survivors. Patients were compared regard-
ing demographics, medical history, clinical and laboratory
ﬁndings, and treatment. The impact of underlying diseases
was determined by the Charlson Comorbidity Index calcu-
lated before the onset of SAB [11], and the overall severity
of the patient’s illness was rated using the Acute Physiology
and Chronic Health Evaluation (APACHE) [12] III score cal-
culated on the basis of available clinical data within the ﬁrst
24 h following SAB onset. The study was approved by the
local ethic committees.
Deﬁnitions
Onset of SAB was deﬁned as the date of collection of the
ﬁrst blood culture yielding the study isolate (index culture).
The origin of the infection was determined by the date of
SAB onset (as deﬁned above) and the date of admission to
the two hospitals participating in the study, except if the
patient was transferred directly from another hospital; in
these last cases, the date of admission to the original inpa-
tient centre was recorded as the date of hospital admission.
Infections were deﬁned as HCA ‡48 h if the index blood
culture had been collected >48 h after hospital admission
and no signs or symptoms of infection had been noted at
admission. Infections with onset within the ﬁrst 48 h of
hospitalization were classiﬁed as HCA <48 h or CA in
accordance with the deﬁnitions of the European Centre for
Disease Prevention and Control [13].
The source of SAB was deﬁned as an infection caused by
a microbial strain identical to the bloodstream isolate, docu-
mented by microbiological and physician ﬁndings. Septic
shock was deﬁned as sepsis associated with organ dysfunc-
tion, accompanied by persistent hypotension following
volume replacement. An inpatient stay of 2 days or more,
during the 12 months preceding the index hospitalization
was considered prior hospitalization. The use of any anti-
microbial for >48 h during the 3 months preceding the index
admission was considered prior antimicrobial therapy. Antibi-
otic treatment empirically prescribed before in vitro suscepti-
bility test results were available was deﬁned as initial
antibiotic treatment and considered ‘inadequate’ (i.e. IIAT)
when treatment with an antibiotic possessing in vitro activity
against the isolated pathogen was absent. No antibiotic ther-
apy or monotherapy with aminoglycosides, trimethoprim, or
rifampicin was deemed inadequate.
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Microbiology analysis
Identiﬁcation at species level of isolates and their susceptibility
proﬁles was obtained with the VITEK 2 (Biome´rieux Inc.,
Hazelwood, MO, USA) and Phoenix (Becton Dickinson Micro-
biology Systems, Sparks, MD, USA) automated systems.
Results of susceptibility testing were interpreted in accordance
with Clinical Laboratory Standards Institute guidelines [14].
Statistical analysis
Continuous variables were compared by Student’s t test if
normally distributed and the Mann–Whitney U test if non-
normally distributed. Categorical variables were evaluated
using chi-square or the two-tailed Fisher’s exact test. The
ORs and 95% CIs were calculated to evaluate the strength
of any association. All the variables associated with SAB in
the univariate analysis (p £0.10) were included in a logistic
regression model, and a backward stepwise approach was
used to identify independent predictors of SAB. Variables
were retained in the ﬁnal model if the p value was £0.05.
All statistical analyses were performed using the INTER-
COOLED STATA program, version 8 for WINDOWS (Stata Corpo-
ration, College Station, TX, USA).
Results
Incidence and population characteristics
A diagnosis of SAB was given in 171 of the 111 455 patients
hospitalized over the period of the study with an incidence of
38 cases per 100 000 patient-days. Six patients were not
included in the analysis because of a lack of sufﬁcient data,
resulting in a ﬁnal number of 165 patients with SAB. The
majority of the infections (67.8%, 112/165) were classiﬁed as
HCA ‡48 h SAB. The remaining 53 were diagnosed within
48 h of admission, but only 24 (14.5%) of these could be classi-
ﬁed as CA SAB. The other 29 (17.5%) were HCA <48 h SAB.
Risk factors analysis
The results of a comparison of the case and control groups
by univariate analysis are shown in Table 1. The HCA ‡48 h
patients were signiﬁcantly older than controls, and long hos-
pital stays, prior hospitalization, prior antibiotic therapy, pre-
vious surgery, and a neutrophil count <500/mm3 were more
common in this group. Compared with controls, the
HCA ‡48 h patients were more likely to have a Charlson
Comorbidity Index ‡3, a central venous catheter, to have
undergone invasive procedures, urinary catheterization, naso-
gastric tube, total parenteral nutrition, previous bacterial
infections, solid tumour, diabetes and chronic renal failure.
In univariate analysis HCA SAB was associated with a
greater proportion of patients with Charlson Comorbidity
Index ‡3, longer hospital stays, prior hospitalization, living in
long-term care facilities, presence of central venous catheter,
previous bacterial infections, solid tumour, diabetes mellitus,
chronic renal failure, HIV infection, and previous radiother-
apy and corticosteroid therapy. Compared with controls,
CA SAB cases had a signiﬁcantly greater proportion of youn-
ger patients, with higher Charlson Comorbidity Index, with
chronic liver diseases, diabetes and HIV infection.
Logistic regression analysis revealed that ﬁve variables
were independently associated with HCA ‡48 h SAB: pres-
ence of central venous catheter, solid tumour, chronic renal
failure, previous hospitalization, and previous antibiotic ther-
apy. Signiﬁcant risk factors for with HCA <48 h SAB were:
Charlson Comorbidity Index ‡3, prior hospitalization, prove-
nience from long-term care facilities, to corticosteroid ther-
apy. The variables signiﬁcantly associated with CA SAB were
diabetes, HIV infection, and chronic liver diseases (Table 2).
Antimicrobial resistance and inadequate initial antimicrobial
treatment
Methicillin-resistant isolates were identiﬁed in 89 of 165
cases (53.9%): the percentage of MRSA was 46% in hospital
A and 59% in hospital B. All MSSA and MRSA isolates were
susceptible to linezolid, tigecycline, quinupristin-dalfopristin,
daptomycin, teicoplanin and vancomycin.
Patients with HCA ‡48 h SAB were signiﬁcantly more
likely to be infected with MRSA isolates than patients with
HCA <48 h SAB (68.7% (77/112) versus 41.3% (12/29),
p 0.006). None of the patients with CA SAB was infected by
MRSA. MRSA isolates were more common in patients hospi-
talized in intensive-care units and surgical wards than in med-
ical wards (70.8% (17/24) and 70.3% (19/27) versus 46.4%
(53/114); p 0.03 and p 0.02, respectively). The main differ-
ences between patients with MRSA and MSSA SAB are indi-
cated in Table 3.
Adequate initial antimicrobial treatment was administered
to 109 (66.1%) patients within 24 h of hospital admission,
and 56 (33.9%) patients received IIAT. Patients with
HCA <48 h SAB were statistically more likely to receive
IIAT than patients with CA or HCA ‡48 h bacteraemia
(44.8% (13/29) versus 33.3% (8/24) and vs. 31.5% (35/112),
respectively). Fig. 1 provides the rates of IIAT treatment by
pathogen distribution.
Outcome
Thirty days after SAB onset, 35 (21.2%) of the 165 patients
had died. The results of the univariate and multivariate
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analyses of risk factors for mortality are shown in Table 4.
Logistic-regression analysis identiﬁed three variables as inde-
pendent predictors of hospital mortality: presentation with
septic shock, infection caused by MRSA, and IIAT.
Discussion
In this prospective study performed in Italy, we observed an
incidence of SAB of 38 per 100 000 patient-days and a
methicillin-resistance rate of 54%. The percentage of MRSA
is higher than that published by the European Antimicrobial
Resistance Surveillance System, which for the whole of Italy
in 2007 reported an incidence of 7.7 MRSA infections per
100 000 patient-days and a methicillin-resistance rate of 34%
[15]. This may be because the two hospitals participating in
the study are among the biggest Italian tertiary-care institu-
tions and have large intensive-care units, and patients in this
setting accumulate risk factors for methicillin resistance [16].
MRSA was found to be HCA ‡48 h acquired in about 85%
of the cases, and the rest of the MRSA acquisition occurred
in outpatients, in whom MRSA was considered HCA <48 h
(no CA SAB was the result of MRSA). This study conﬁrms
previous ﬁndings that MRSA rarely causes CA SAB in adults
[17]. One of the main ﬁndings of this study is that only 13%
of patients with MRSA bacteraemia were outpatients with
previous healthcare contacts; this proportion is lower than
that found in a similar Spanish study [18]. This emphasizes
the importance of chronic colonization after MRSA acquisi-
tion in healthcare facilities.
There are a number of important observations regarding
the epidemiological proﬁle of MRSA bacteraemia in our
region. MRSA was responsible for one of the two incidents
of SAB reported in 2007 in our Institutions. This ﬁnding has
important implications for empirical antimicrobial therapy for
patients with suspected S. aureus infections.
The 21% 30-day in-hospital mortality for patients with
SAB reported here was similar to the 16.2–23.2% reported
in other studies [19,20]. Our data reveal that the mortality
TABLE 3. Characteristics of the 165 bacteraemia caused by
Staphylococcus aureus stratiﬁed by methicillin resistance
p valueVariables MRSA (n = 89) MSSA (n = 76)
Male sex 59 (66.3) 43 (56.6) 0.20
Age, years (mean ± SD) 65 ± 15 59 ± 18 0.04
Ward at SAB onset
Medicine 53 (59.6) 61 (80.3) 0.004
Surgery 19 (21.4) 8 (10.5) 0.06
Intensive-care unit 17 (19.1) 7 (9.2) 0.07
Epidemiological category
Healthcare-associated ‡48 h l 77 (86.5) 35 (46.14) <0.001
Healthcare-associated <48 h 12 (13.4) 17 (22.3) 0.13
Community-acquired 0 (0.0) 24 (31.5) <0.001
Previous use of antibioticsa 53 (59.6) 25 (32.9) 0.001
Source of bacteraemia
Central venous catheter 12 (13.5) 11 (14.5) 0.86
Urinary tract 1 (1.1) 2 (2.6) 0.47
Lower respiratory tract 5 (5.6) 2 (2.6) 0.34
Surgical wound 2 (2.3) 2 (2.6) 0.87
Skin and soft tissues 5 (5.6) 5 (6.6) 0.79
Unknown 53 (59.6) 51 (67.1) 0.32
Time to discharge, days (mean ± SD) 33 ± 31 29 ± 22 0.32
Inadequate antimicrobial treatment 39 (43.8) 17 (22.4) 0.004
Apache III >15 42 (47.1) 38 (50) 0.71
Charlson Comorbidity Index ‡3 44 (49.4) 34 (44.7) 0.55
Presentation with septic shock 26 (29.2) 8 (10.5) 0.003
Initial treatment failure 29 (32.6) 8 (10.5) 0.001
30-day mortality 29 (32.5) 6 (7.9) <0.001
Data are given as number of patients (%) unless stated otherwise.
MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant
Staphylococcus aureus; SAB, Staphylococcus aureus bacteraemia.
aWithin 30 days of the onset of bacteraemia.
TABLE 2. Logistic regression analysis of risk factors for bac-
teraemia caused by Staphylococcus aureus stratiﬁed by epi-
demiological category
Variables p OR (95% CI)
HCA ‡48 h
Solid tumour <0.001 3.95 (2.02–7.72)
Chronic renal failure <0.001 4.03 (1.92–8.44)
Central venous catheter <0.001 3.69 (2.15–6.34)
Previous hospitalization <0.001 3.79 (2.20–6.51)
Previous antibiotic therapy 0.004 2.25 (1.30–3.88)
HCA <48 h
Admission from LTCF 0.04 6.61 (1.02–42.89)
Previous hospitalization 0.007 5.67 (1.61–19.98)
Charlson Comorbidity Index ‡3 0.01 4.98 (1.38–18.07)
Corticosteroid therapy 0.02 4.78 (1.26–18.12)
Community-acquired
Diabetes mellitus 0.008 6.21 (1.62–23.77)
HIV infection 0.01 11.03 (1.79–67.76)
Chronic liver disease 0.01 6.00 (1.54–23.37)
HCA, healthcare-associated; LTCF, long-term care facility; HIV, Human immuno-
deﬁciency virus.
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FIG. 1 Inadequate initial antimicrobial treatment (%). Rates of inade-
quate initial antimicrobial treatment in patients with commu-
nity-acquired (CA), healthcare-associated ‡48 h (HCA ‡48 h) and
healthcare-associated <48 h (HCA <48 h) Staphylococcus aureus bac-
teraemia (SAB) according to methicillin resistance. MSSA, methicillin-
susceptible S. aureus; MRSA, methicillin-resistant S. aureus.
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associated with MRSA bacteraemia is signiﬁcantly higher than
that associated with MSSA bacteraemia (32.5% versus 7.9%,
p < 0.001). Several studies have investigated the differences
in the mortality rates for patients who have MRSA bactera-
emia compared with patients who have MSSA bacteraemia
[21,22]. In a recent big multicentre prospective European
study when the outcomes from MRSA and MSSA bactera-
emia were compared, an effect attributable to methicillin
resistance was found for 30-day mortality (OR = 1.8; p 0.04)
[8]. In our study the underlying severity of illness in the
MRSA group was similar to that in the susceptible group, it
may be presumed that bacteraemia by MRSA may have a
worse prognosis because of the IIAT. The impact of appro-
priate empirical therapy against MRSA on survival has been
explored in several studies including only patients with bac-
teraemia; their results were contradictory [23,24]. Other
studies have evaluated the importance of empirical therapy
in MRSA bacteraemia and IIAT was associated with increased
mortality [25,26].
We analysed the inﬂuence of IIAT on outcome of SAB.
After controlling for the underlying conditions, we found that
presentation with septic shock, MRSA and IIAT were associ-
ated with increased mortality. In particular, the rates of
patients with HCA <48 h SAB who received IIAT were
about 60% and 30% for MRSA and MSSA cases, respectively,
higher than those found for HCA ‡48 h SAB. Therefore,
empirical antibiotic therapy against SA needs to be consid-
ered not only for patients with HCA ‡48 h infection where
the risk of MRSA is usually higher, but also for patients with
HCA <48 h infections, especially if there has been recent
contact with healthcare facilities. Early and precise prediction
of both S. aureus severe infection and methicillin susceptibil-
ity is needed to allow for appropriate empirical therapy of
MRSA or optimal (beta-lactam) treatment of MSSA infec-
tions, avoiding superﬂuous use of glycopeptides.
As in other studies, all isolates were susceptible to vanco-
mycin, linezolid, daptomycin and tigecycline [27]. We did not
detect vancomycin hetero-resistance, in agreement with a
recent study from a UK hospital [27].
Our current data support previous observations with
respect to risk factors for the acquisition of SAB. However,
although several studies have noted a high frequency of
chronic comorbid illnesses among patients with SAB, only a
few studies have quantiﬁed the actual magnitudes of risks
[28,29]. The present study adds two main novel observa-
tions. First, the distribution and magnitude of comorbidity
risk factors for HCA ‡48 h or HCA <48 h SAB are different
(Table 2). Second, we identiﬁed that admission from a long-
term care facility is associated with a 16-fold increased risk
for HCA <48 SAB. The spread of MRSA in long-term care
facilities increases the reservoir of this organism in the
healthcare setting, and residents transferred from long-term
care facilities account for a large part of the burden of hospi-
talized MRSA infections [30,31].
Although we have shown that there are some differences
between HCA ‡48 h and HCA <48 h SAB, S. aureus infec-
tions are predominant in subjects with concomitant medical
problems and in those exposed to previous hospitalization.
Our experience conﬁrmed the role of previous exposure to
antibacterials in promoting acquisition of S. aureus infections.
This study has several limitations. First, it was conducted
only in two centres; therefore unknown risk factors for
TABLE 4. Univariate and multivariate analysis of factors associated with 30 days in-hospital mortality among patients with
Staphylococcus aureus.bacteraemia
Variable
n (%) of patients
p value OR (95% CI)Dead (n = 35) Survivors (n = 130)
Univariate analysis
Male sex 24 (68.5) 78 (60) 0.35 1.45 (0.62–3.57)
Age, years (mean ± SD) 65 ± 28 61 ± 42 0.16 –
Chronic renal failure 11 (31.4) 31 (23.8) 0.36 1.46 (0.57–3.52)
Ward
Medicine 19 (54.2) 95 (73.1) 0.03 043 (0.18–1.02)
Surgery 8 (22.8) 19 (14.6) 0.24 1.73 (0.58–4.68)
Intensive-care unit 8 (22.8) 16 (12.3) 0.11 2.11 (0.70–5.87)
Epidemiological category
Healthcare-associated ‡48 h 25 (71.4) 87 (66.9) 0.61 1.23 (0.51–3.15)
Healthcare-associated <48 h 7 (20) 22 (16.9) 0.67 1.22 (0.40–3.36)
Community-acquired 3 (8.6) 21 (16.2) 0.25 0.48 (0.08–1.79)
Methicillin resistance 29 (82.9) 60 (46.2) <0.001 5.63 (2.09–17.57)
Inadequate antimicrobial treatment 21 (60) 35 (26.9) <0.001 4.07 (1.74–9.60)
Apache III >15 20 (57.1) 60 (46.1) 0.24 1.55 (0.68–3.56)
Charlson Comorbidity Index ‡ 3 21 (60) 57 (43.8) 0.08 1.92 (0.84–4.45)
Presentation with septic shock 17 (48.6) 17 (13.1) <0.001 6.27 (2.49–15.68)
Multivariate analysis
Presentation with septic shock – – 0.002 4.14 (1.69–10.14)
Methicillin resistance – – 0.006 4.00 (1.47–10.82)
Inadequate antimicrobial treatment – – 0.01 2.79 (1.19–6.52)
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mortality might have been unequally distributed between the
different groups. Second, the standard when determining
antibiotic efﬁcacy is a randomized controlled trial. Without
randomization, physicians and patients select therapies in
ways that can introduce substantial confounding. Third, the
risks for other treatment factors that may have contributed
to adverse outcomes, such as improper dosing and other
procedures were not included in the analysis. Finally, the
severity of illness was measured within 24 h after the onset
of bacteraemia and, therefore, it should not reﬂect the
severity status before the infection onset.
In conclusion, over half of patients with S. aureus blood-
stream infection in this study have MRSA strains and in these
cases presentation with septic shock and inappropriate
empirical therapy was associated with increased mortality.
Clinicians should be aware that appropriate antimicrobial
therapy should be immediately prescribed to reduce the risk
of a poor outcome when bloodstream infection caused by
S. aureus is suspected, in the following settings: patients arriv-
ing from long-term care facilities or with previous hospital-
ization, previous antibiotic exposure and with important
comorbidities (e.g. solid tumour, chronic renal failure, diabe-
tes). Our results support prompt initiation of antibiotics tar-
geted against MRSA in cases of suspected hospital and
healthcare-associated SAB, especially in patients with signs of
severe sepsis.
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